Abstract 4572
Background
Digestive Cancers Europe (DiCE), a European digestive cancers patient organisation, planned and carried out an international survey on the Unmet Needs of Patients Living with mCRC. The aim was to better understand the challenges, needs, and health-related quality of life (HRQoL) of those living with mCRC in 15 European countries.
Methods
Nurses and clinicians together with DiCE partner organisations recruited patients to fill in the survey (online or paper). Data collected included information on demographics, the disease discovery, diagnosis and treatment and support received. Questions on discovery and diagnoses covered reasons for contacting physicians, symptoms experience, the lag time between first symptoms and seeking clinical help, and misdiagnosis. Single data entry from paper surveys was executed by DiCE. Data were analyzed descriptively.
Results
883 surveys were collected and analyzed: Austria (8), Belgium (65), Cyprus (57), Hungary (103), Ireland (3), Italy (36), Germany (22), Netherlands (40), Norway (1), Poland (163), Portugal (24), Serbia (170), Spain (112), Turkey (26) and the UK (53). Item completion rates were high. Mean time with mCRC was 2yrs. Diagnosis was established at a routine visit for 20%; at visits due to CRC-related or non-CRC related symptoms (41% and 26%); or at emergency hospitalization (19%); with only 5% through screening. CRC symptom awareness was very low: on average only 28% of patients knew before what symptoms CRC may present. Although 39% of patients waited <1 month from observing symptoms, 31% waited 1–3 months, 12% waited 3–6 months and the rest even longer. Similar time distribution was observed for diagnosis. Misdiagnoses was indicated by 25%. Patient satisfaction was relatively high: 43% of patients were very satisfied with the process of establishing a diagnosis, with large variation across countries.
Conclusions
Awareness of patients with CRC is low, with few respondents recognising symptoms and seeking help without delay. Misdiagnosis levels are still high. Despite the existence of various screening in surveyed countries, awareness and compliance rates are low. The conditions of the discovery of mCRC need to be improved both on the patient awareness and the clinical side.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
EuropaColon / Digestive Cancers Europe.
Funding
Merck, BMS, Sandoz and Sirtex.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5612 - Evaluation of germ line mutational status among women with triple-negative breast cancer in Russia
Presenter: Elena Shagimardanova
Session: Poster Display session 2
Resources:
Abstract
4142 - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
Presenter: Alberto Ocaña
Session: Poster Display session 2
Resources:
Abstract
1733 - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer
Presenter: Jianfei Fu
Session: Poster Display session 2
Resources:
Abstract
1978 - A Nomogram to Predict Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Blood Indicators
Presenter: Fanrong Zhang
Session: Poster Display session 2
Resources:
Abstract
3062 - Identification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells
Presenter: Sujin Yang
Session: Poster Display session 2
Resources:
Abstract
5274 - Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and its Association with Clinicopathological Parameters in Invasive Breast Cancers
Presenter: Gayathri Devi
Session: Poster Display session 2
Resources:
Abstract
1324 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients
Presenter: Soo Youn Bae
Session: Poster Display session 2
Resources:
Abstract
4877 - Correlation of clinical and pathological features with the tumour microenvironment in DCIS. An institutional experience
Presenter: Ann Eapen
Session: Poster Display session 2
Resources:
Abstract
2471 - Correlation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival
Presenter: Ariadna Gasol Cudos
Session: Poster Display session 2
Resources:
Abstract
2632 - Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer
Presenter: Norio Masumoto
Session: Poster Display session 2
Resources:
Abstract